Urologic Oncology Fellow @MSKCancerCenter @UrologyMSK | Alum @Brady_Urology @HarvardMed @Yale
New York, NY
Joined December 2018
- Tweets264
- Following563
- Followers693
- Likes2.4K
Sean Fletcher retweeted
Want to learn about the the largest and oldest @UroOnc fellowship? Sign up for our virtual open house on Nov 11th at 7 pm. Hear from our PD and current fellows about our mix of open and MIS surgery, unparalleled research opportunities and mentorship.
forms.gle/Gdf4RntMQefHvhwKA
Sean Fletcher retweeted
🚨 Divergent Differentiation & Histologic Subtypes in UTUC
👥 3,441 patients from 22 institutions undergoing radical nephroureterectomy.
🔬 Divergent differentiation showed outcomes comparable to stage-matched pure urothelial carcinoma, while histological subtypes were associated with particularly unfavorable outcomes, emphasizing the importance of pathological charecterization. 🎯
Congratulations to the authors for multi-institutional collaborative effort!
🔗 doi.org/10.1016/j.urolonc.20…
@PallaufM @potretzke @SBoorjian @MRoupret @Hoomandjaladat @alirezaghoreifi @DrShariat @Ric_Campi @nirmishsingla @UrolOncol
Out now in @BJUIjournal: our study on re-evaluating active surveillance eligibility through measurement of the total length of Gleason pattern 4 on biopsy, which provides improved & more nuanced risk prediction compared to GG or NCCN groups
bjui-journals.onlinelibrary.…
mm pattern 4 on biopsy far superior predictor of prostate cancer outcome than stage, grade, PSA, cores. We show using mm criteria rather than "favorable intermediate risk" would increase the number of US men eligible for active surveillance by >50,000. bjui-journals.onlinelibrary.…
Sean Fletcher retweeted
Oral boards prep hasn't appreciably changed in decades, so I built MockUro, an AI examiner that walks you through ~250 canonical urology cases in Socratic Q&A format, grades your free-form answers across key domains, and adapts your study plan to your weak spots
🧵
Thanks @urogoldjournal for publishing our work on MRI-targeted biopsy for suspected local recurrence after RP. Biopsy prior to salvage RT (esp in equivocal cases) can guide dose escalation strategies @BehfarEhdaieMD @BCottaMD @HimanshuNagarMD @UrologyMSK
goldjournal.net/article/S009…
Our review on neoadjuvant intraprostatic immunotherapy for high-risk localized prostate cancer, out now in @NatRevUrol. @NickPickersgill @CGaffMD @UrologyMSK
nature.com/articles/s41585-0…
Incredible experience with @UrologyMSK @HartfordHealthC CESI: major vascular repair, RPLND & open partial nephrectomy techniques, GU recon, and more. Great time sharpening skills with co-fellows and learning from world-class faculty
A stellar week at our @UrologyMSK open skills training program. Thx @HartfordHealthC CESI center for partnering @MSKCancerCenter @VinceDAndreaMD @NFryden @SeanFletcherMD
Becky Sager
Jonathan Suderman @aghasemzadeh1 @eugene_pietzak @bca_md @HongTruongMD @EKChaMD @RichMatulewicz
Sean Fletcher retweeted
New in @BJUIjournal: PSMA-PET/CT in pN1 prostate cancer
• Poor sensitivity for LNI in high-risk pts; negative PSMA-PET does not justify omitting PLND
• PSMA+ nodal disease = nearly guaranteed BCR & radiographic progression (1-yr BCR ~84%)
• Do these patients need adjuvant treatment intensification? Prospective trials needed
@UrologyMSK @SeanFletcherMD @VickersBiostats
bjui-journals.onlinelibrary.…
Sean Fletcher retweeted
"Due to low sensitivity, PSMA-PET/CT without evidence of nodal disease does not obviate the need for PLND" BUT "PSMA-avid nodal disease portends ... nearly inevitable ... recurrence and radiographic progression, supporting treatment intensification." bjui-journals.onlinelibrary.…
Sean Fletcher retweeted
More insights from @MSKCancerCenter re: N+ #prostatecancer. Confirming PSMA PET ≠ PLND, PLND alone is not commonly curative, tx needs to be multimodal. #GU26 @SeanFletcherMD
Sean Fletcher retweeted
Interested in learning about the oldest and largest urologic oncology fellowship in the world? Join us in our virtual open house wed Nov 12th at 7 pm EST Hear from faculty and current fellows!!
mskcc.org/hcp-education-trai…
Sign up: forms.gle/bE5nEzCuaczcVD5D7
Sean Fletcher retweeted
New in @JAMAOnc: Our study of >11,000 PLCO participants shows that ~25% of elevated PSA values fall below threshold within a year, but persistent elevations rarely do (<10%), and should proceed directly to further eval.
@SigridCarlsson @MariaPereMD @UrologyMSK @VickersBiostats
Many elevated PSA levels normalize within a year, but consistently high values warrant direct diagnostic evaluation without repeated testing.
ja.ma/488K3S3
Check out our Clinical Consultation Guide on Neoadjuvant Chemotherapy for Upper Tract Urothelial Cancer, published in @EurUrolFocus
@nirmishsingla @JCensits
eu-focus.europeanurology.com…
Sean Fletcher retweeted
Family History of Prostate, Breast, Ovarian, and/or Pancreatic Cancer and Associations with Grade Reclassification in a Large Prostate Cancer Active Surveillance Cohort
euoncology.europeanurology.c…
In a prospective cohort of 1,421 prostate cancer patients on active surveillance, family history of #ProstateCancer (FH-Pr) was associated with a higher risk of grade reclassification, including progression to Gleason grade ≥3, whereas family history of breast, ovarian, or pancreatic cancer (FH-BOPa) was not. Among 349 patients who underwent radical prostatectomy, no family history was linked to adverse pathological features.
These findings suggest that patients with a FH of prostate cancer can remain on active surveillance but may benefit from closer monitoring.
@ClaireDlc
@SeanFletcherMD
@KatarzynaMacura
@LotanLab
William B. Isaacs @brady_Urology
Christian P. Pavlovich
@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@nataliagandur
@bavilima
Major congrats to @LoganGalanskyMD & huge win for @BostonChildrens !
Big Congratulations to @LoganGalanskyMD for matching @BostonChildrens Pediatric Urology Fellowship! A former AUA Holtgrewe Legislative Fellow, meticulous surgeon, and future leader. We are all so proud of Logan!!
Out in @BJUIjournal: Retro cohort study on detection of GG2+ PCa on systematic biopsy outside of MRI ROI (n=481 biopsies @brady_urology)
- 6.4% with GG2+ outside of ROI
- 1.5% with GG2+ contralateral to ROI
- No association w baseline factors (e.g. PSA-D)
bjui-journals.onlinelibrary.…
Honor and a pleasure to end residency with the Peds team 🫡 @DrG_PedsUro @heathernoellemc @dr_chad11 @CharlotteWuMD @VictoriaMaxon @madip_pac
Final Chief send off for this year, this time for @HopkinsMedicine @brady_urology’s @SeanFletcherMD. Cool, calm and collected, I’m convinced nothing can phase him. @UrologyMSK and @MSKCancerCenter are getting a thoughtful, talented surgeon and future leader in Urology.
Feels a bit surreal to be done — so grateful to have trained @brady_urology with world class faculty, staff & co-residents!
Huge congrats to this outstanding chief class @SeanFletcherMD, @urogabe, and Katie Mahon on completing their residency today! We are so proud of you! @brady_urology @allaf_mo
